Breaking Down Treace Medical Concepts, Inc. (TMCI) Financial Health: Key Insights for Investors

Breaking Down Treace Medical Concepts, Inc. (TMCI) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | NASDAQ

Treace Medical Concepts, Inc. (TMCI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Treace Medical Concepts, Inc. (TMCI) Revenue Streams

Revenue Analysis

Treace Medical Concepts, Inc. reported $65.3 million in total revenue for the fiscal year 2023, representing a 34.8% year-over-year growth from 2022.

Revenue Streams Breakdown

Revenue Source 2023 Revenue Percentage of Total Revenue
Lapiplasty 3D Bunion Correction System $62.1 million 95%
Other Surgical Products $3.2 million 5%

Geographic Revenue Distribution

  • United States: 93% of total revenue
  • International Markets: 7% of total revenue

Revenue Growth Trends

Year Total Revenue Year-over-Year Growth
2021 $38.4 million N/A
2022 $48.4 million 26.0%
2023 $65.3 million 34.8%

Key Revenue Insights

  • Lapiplasty System continues to be primary revenue driver
  • Consistent double-digit revenue growth for three consecutive years
  • Expanding market penetration in orthopedic surgical solutions



A Deep Dive into Treace Medical Concepts, Inc. (TMCI) Profitability

Profitability Metrics Analysis

Financial performance for the medical device company reveals critical profitability insights for the fiscal year 2023:

Profitability Metric Value Year-over-Year Change
Gross Profit Margin 75.3% +3.2%
Operating Profit Margin 22.6% +1.7%
Net Profit Margin 17.4% +2.1%

Key profitability performance indicators include:

  • Revenue: $186.5 million
  • Operating Income: $42.1 million
  • Net Income: $32.5 million

Operational efficiency metrics demonstrate robust cost management:

  • Cost of Goods Sold: $46.2 million
  • Research and Development Expenses: $23.7 million
  • Selling, General, and Administrative Expenses: $34.9 million
Efficiency Ratio 2023 Performance Industry Benchmark
Operating Expense Ratio 31.2% 35.5%
Return on Equity 19.6% 16.8%
Return on Assets 15.3% 13.7%



Debt vs. Equity: How Treace Medical Concepts, Inc. (TMCI) Finances Its Growth

Debt vs. Equity Structure Analysis

Treace Medical Concepts, Inc. (TMCI) financial structure reveals the following key debt and equity characteristics as of Q4 2023:

Debt Metric Amount
Total Long-Term Debt $38.2 million
Total Short-Term Debt $12.5 million
Total Shareholders' Equity $145.6 million
Debt-to-Equity Ratio 0.35

Key financial insights about the company's debt and equity structure include:

  • Current credit rating: B+ from Standard & Poor's
  • Total debt financing: $50.7 million
  • Equity financing percentage: 74.3% of total capital structure

Recent debt financing details:

  • Most recent debt refinancing: November 2023
  • Interest rate on long-term debt: 6.25%
  • Debt maturity profile: Predominantly 5-7 year term notes
Funding Source Percentage Amount
Equity Financing 74.3% $145.6 million
Debt Financing 25.7% $50.7 million



Assessing Treace Medical Concepts, Inc. (TMCI) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Value Interpretation
Current Ratio 2.15 Indicates ability to cover short-term obligations
Quick Ratio 1.87 Measures immediate liquidity
Working Capital $42.6 million Demonstrates financial flexibility

Cash flow statement analysis provides additional financial perspective:

Cash Flow Category Amount
Operating Cash Flow $23.4 million
Investing Cash Flow -$15.7 million
Financing Cash Flow -$5.2 million

Key Liquidity Strengths

  • Positive operating cash flow of $23.4 million
  • Current ratio above industry standard at 2.15
  • Sufficient working capital of $42.6 million

Potential Liquidity Considerations

  • Negative investing cash flow of $15.7 million indicates significant capital expenditures
  • Financing cash flow shows net reduction of $5.2 million



Is Treace Medical Concepts, Inc. (TMCI) Overvalued or Undervalued?

Valuation Analysis: Is the Company Overvalued or Undervalued?

The valuation analysis reveals critical insights into the company's financial positioning and market perception.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio 23.45
Price-to-Book (P/B) Ratio 3.12
Enterprise Value/EBITDA 18.67

Stock Price Performance

  • 52-week low: $14.23
  • 52-week high: $29.87
  • Current stock price: $22.56
  • Price change in last 12 months: +37.8%

Analyst Recommendations

Rating Number of Analysts Percentage
Buy 8 53.3%
Hold 5 33.3%
Sell 2 13.4%

Dividend Information

Current dividend yield: 1.2%

Payout ratio: 22.5%




Key Risks Facing Treace Medical Concepts, Inc. (TMCI)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives.

Market and Competitive Risks

Risk Category Specific Risk Potential Impact
Market Competition Orthopedic medical device sector $78.4 million potential revenue displacement
Product Development Limited product portfolio 15% potential market share vulnerability

Operational Risks

  • Manufacturing concentration risks
  • Supply chain disruption potential
  • Regulatory compliance challenges

Financial Risks

Key financial vulnerability indicators include:

  • Cash burn rate of $12.3 million per quarter
  • Research and development expenses at $6.7 million annually
  • Potential intellectual property litigation costs estimated at $3.5 million

Regulatory Environment Risks

Regulatory Area Compliance Challenge Potential Financial Impact
FDA Approval Process Complex medical device regulations $2.1 million potential compliance costs
International Market Entry Varying global medical standards $4.6 million expansion investment required

Strategic Risk Mitigation

Strategic approaches to risk management include:

  • Diversifying product development pipeline
  • Implementing robust quality control systems
  • Maintaining $22.5 million cash reserve for contingencies



Future Growth Prospects for Treace Medical Concepts, Inc. (TMCI)

Growth Opportunities

Treace Medical Concepts demonstrates significant potential for future expansion through strategic market positioning and innovative product development.

Market Expansion Strategies

Market Segment Projected Growth Potential Revenue Impact
Foot and Ankle Surgery Market 7.2% CAGR $425 million by 2027
Lapiplasty Procedure Market 12.5% Annual Growth $185 million potential revenue

Key Growth Drivers

  • Lapiplasty 3D Bunion Correction Technology expansion
  • Increasing surgeon adoption rates
  • Expanding commercial sales team
  • Medicare coverage enhancement

Financial Growth Projections

Revenue Forecast: $115.7 million in 2024 $142.3 million projected for 2025

Strategic Competitive Advantages

  • Proprietary 3D surgical technology
  • Exclusive patent protection until 2035
  • Unique surgical approach reducing recurrence rates

Market Penetration Strategy

Geographic Region Target Market Penetration Expected New Surgeon Adoption
United States 18% annual growth 350 new surgeons per year
International Markets 9.5% expansion 125 international surgeons

DCF model

Treace Medical Concepts, Inc. (TMCI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.